ESR1
EstablishedESR1 mutations are a major acquired-resistance mechanism in hormone-receptor-positive breast cancer, now a treatment-selection biomarker.
ESR1 is the gene for the estrogen receptor that breast cancer hormone therapy targets. When this gene mutates, the cancer can become resistant to standard treatment — but doctors can now test for this and switch to newer pills specifically designed to work despite the mutation.
ESR1 encodes the estrogen receptor, the central target of hormone therapy in estrogen receptor-positive breast cancer; mutations in this gene are a major mechanism by which tumors become resistant to standard endocrine therapy.
ESR1 mutations emerge in up to 50% of hormone receptor-positive metastatic breast cancer patients after first-line aromatase inhibitor treatment, indicating acquired resistance and predicting reduced benefit from continuing standard endocrine therapies.
Detected via tumor or liquid biopsy genomic testing; ESR1 mutation status has become a genuine treatment-selection biomarker rather than just a research finding, guiding the choice of next-line endocrine therapy.
Elacestrant became the first FDA/EMA-approved oral selective estrogen receptor degrader (SERD) specifically for ESR1-mutant disease, based on the EMERALD trial demonstrating improved progression-free survival; several more oral SERDs (imlunestrant, camizestrant, giredestrant) are in the pipeline as of 2025-2026, reflecting a rapidly expanding treatment class built directly around this biomarker.
Directly created a new FDA-approved drug class (oral SERDs) built specifically around this mutation.
- PMC. (2024). Clinical and Genomic Factors Associated with Elacestrant Outcomes in ESR1-Mutant Metastatic Breast Cancer.
- ESMO Open. (2024). Elacestrant in ESR1-mutant, endocrine-responsive metastatic breast cancer.